John Overdeck’s Collegium Pharmaceutical COLL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.86M | Sell |
106,704
-483,412
| -82% | -$16.5M | ﹤0.01% | 2394 |
|
|
2026
Q1 | $19.5M | Buy |
590,116
+224,017
| +61% | +$9.48M | 0.02% | 961 |
|
|
2025
Q4 | $17M | Buy |
366,099
+96,781
| +36% | +$4.05M | 0.02% | 808 |
|
|
2025
Q3 | $9.42M | Buy |
269,318
+242,310
| +897% | +$8.42M | 0.01% | 998 |
|
|
2025
Q2 | $799K | Sell |
27,008
-48,216
| -64% | -$1.38M | ﹤0.01% | 2366 |
|
|
2025
Q1 | $2.25M | Buy |
75,224
+4,401
| +6% | +$134K | ﹤0.01% | 1659 |
|
|
2024
Q4 | $2.03M | Sell |
70,823
-135,582
| -66% | -$4.49M | ﹤0.01% | 1704 |
|
|
2024
Q3 | $7.98M | Sell |
206,405
-48,368
| -19% | -$1.72M | 0.02% | 857 |
|
|
2024
Q2 | $8.2M | Buy |
254,773
+28,967
| +13% | +$1M | 0.02% | 793 |
|
|
2024
Q1 | $8.77M | Sell |
225,806
-34,006
| -13% | -$1.19M | 0.02% | 704 |
|
|
2023
Q4 | $8M | Sell |
259,812
-89,194
| -26% | -$2.23M | 0.02% | 769 |
|
|
2023
Q3 | $7.8M | Sell |
349,006
-16,616
| -5% | -$379K | 0.02% | 694 |
|
|
2023
Q2 | $7.86M | Buy |
365,622
+6,413
| +2% | +$146K | 0.02% | 737 |
|
|
2023
Q1 | $8.62M | Buy |
359,209
+245,663
| +216% | +$6.51M | 0.02% | 647 |
|
|
2022
Q4 | $2.63M | Buy |
+113,546
| New | +$2.29M | 0.01% | 1169 |
|
|
2022
Q2 | – | Sell |
-28,734
| Closed | -$585K | – | 2575 |
|
|
2022
Q1 | $585K | Buy |
+28,734
| New | +$543K | ﹤0.01% | 1946 |
|
|
2021
Q3 | – | Sell |
-41,734
| Closed | -$987K | – | 4298 |
|
|
2021
Q2 | $987K | Sell |
41,734
-774
| -2% | -$17.9K | ﹤0.01% | 2490 |
|
|
2021
Q1 | $1.01M | Buy |
+42,508
| New | +$1.01M | ﹤0.01% | 2302 |
|
|
2020
Q3 | – | Sell |
-112,538
| Closed | -$1.97M | – | 3155 |
|
|
2020
Q2 | $1.97M | Sell |
112,538
-69,375
| -38% | -$1.36M | 0.01% | 1108 |
|
|
2020
Q1 | $2.97M | Buy |
181,913
+118,977
| +189% | +$2.46M | 0.02% | 755 |
|
|
2019
Q4 | $1.29M | Buy |
+62,936
| New | +$1.05M | ﹤0.01% | 1951 |
|
|
2019
Q2 | – | Sell |
-69,072
| Closed | -$1.05M | – | 3372 |
|
|
2019
Q1 | $1.05M | Buy |
+69,072
| New | +$1.11M | ﹤0.01% | 1797 |
|
|
2018
Q4 | – | Sell |
-228,319
| Closed | -$3.37M | – | 3049 |
|
|
2018
Q3 | $3.37M | Buy |
228,319
+214,116
| +1,508% | +$3.8M | 0.01% | 1143 |
|
|
2018
Q2 | $339K | Buy |
14,203
+3,916
| +38% | +$96.3K | ﹤0.01% | 2877 |
|
|
2018
Q1 | $263K | Sell |
10,287
-53,436
| -84% | -$1.27M | ﹤0.01% | 2840 |
|
|
2017
Q4 | $1.18M | Buy |
+63,723
| New | +$913K | ﹤0.01% | 1856 |
|
|
2016
Q1 | – | Sell |
-8,500
| Closed | -$234K | – | 2835 |
|
|
2015
Q4 | $234K | Buy |
+8,500
| New | +$179K | ﹤0.01% | 2380 |
|
Other funds holding COLL
JT
EAM
John Overdeck's COLL Position: Q2 2026 in Review
John Overdeck reduced its Collegium Pharmaceutical (COLL) stake by 82% in Q2 2026, selling an estimated $16.5M and leaving 106,704 shares worth $3.86M. The position accounts for ﹤0.01% of the portfolio, ranked #2394.
John Overdeck first reported a position in COLL in Q4 2015 and has held it in 27 quarters since. The position peaked at $19.5M in Q1 2026. 277 funds tracked by Wall St. Rank hold COLL as of Q2 2026.
- John Overdeck held 106,704 shares of Collegium Pharmaceutical worth $3.86M as of Q2 2026.
- John Overdeck sold 483,412 Collegium Pharmaceutical shares in Q2 2026, an estimated $16.5M.
- Collegium Pharmaceutical made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #2394 holding.
- John Overdeck first reported a position in Collegium Pharmaceutical in Q4 2015 and has held it in 27 quarters since.
- John Overdeck's Collegium Pharmaceutical position peaked at $19.5M in Q1 2026.
- 277 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.
Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.